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Abstract: Quinolinic acid (QUIN), an endogenous metabolite of the kynurenine pathway, is involved in several neurological disorders, 
including Huntington’s disease, Alzheimer’s disease, schizophrenia, HIV associated dementia (HAD) etc. QUIN toxicity involves 
several mechanisms which trigger various metabolic pathways and transcription factors. The primary mechanism exerted by this exci-
totoxin in the central nervous system (CNS) has been largely related with the overactivation of N-methyl-D-aspartate receptors and 
increased cytosolic Ca2+ concentrations, followed by mitochondrial dysfunction, cytochrome c release, ATP exhaustion, free radical 
formation and oxidative damage. As a result, this toxic pattern is responsible for selective loss of middle size striatal spiny GABAergic 
neurons and motor alterations in lesioned animals. This toxin has recently gained attention in biomedical research as, in addition to its 
proven excitotoxic profile, a considerable amount of evidence suggests that oxidative stress and energetic disturbances are major con-
stituents of its toxic pattern in the CNS. Hence, this profile has changed our perception of how QUIN-related disorders combine different 
toxic mechanisms resulting in brain damage. This review will focus on the description and integration of recent evidence supporting old 
and suggesting new mechanisms to explain QUIN toxicity.
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Introduction
Is quinolinic acid (QUIN or 2,3-pyridine-dicarboxylic 
acid)  an  “enemy  at  home”?  Indeed,  it  could  be: 
the  presence  of  this  endogenous  molecule  in  the 
brain constitutes a major risk because under normal 
physiological conditions QUIN is a component of a 
major metabolic pathway of tryptophan degradation 
and  can  modulate  some  local  events  in  the  CNS. 
However,  under  pathological  conditions,  it  is 
capable of inducing a potent neurotoxic pattern by 
different  mechanisms,1,2  therefore  representing  a 
latent  menace  for  neurodegeneration  by  means  of 
the  brain’s  own  “tools”.  QUIN  is  an  extensively 
studied  endogenous  metabolite  of  the  tryptophan 
degradation pathway, also known as the kynurenine 
pathway  (KP).  Under  normal  conditions,  QUIN 
is  produced  as  a  downstream  transient  metabolite 
of  tryptophan  involved  in  adenine  dinucleotide 
(NAD+)  synthesis  as  under  regular  conditions  KP 
catalyzes L-tryptophan into NAD+. In mammals, the 
majority  of  tryptophan  comes  from  dietary  intake, 
and is metabolized by the KP. The relevance of this 
pathway is a topic often reviewed, and is magnified by 
evidence demonstrating the formation of two major 
neuroactive metabolites: kynurenic acid (KYNA)—an 
endogenous N-methyl-D-aspartate receptor (NMDAr) 
antagonist with the ability of modulating α7 nicotinic 
receptors—and  QUIN—an  endogenous  NMDAr 
agonist.  In  addition,  the  KP  is  responsible  for  the 
formation  of  other  metabolites  exhibiting  redox 
activity, including 3-hydroxykynurenine (3-HK) and 
3-hydroxyanthranilic acid (3-HAA). Whilst 3-HK is 
accepted as a pro-oxidant metabolite, there is also 
recent evidence showing that both 3-HK and 3-HAA 
are antioxidants acting as nitric oxide scavengers.3
In this minireview, the findings collected from several 
groups using QUIN as a toxic tool in neurosciences 
will be discussed. Particular attention will be given 
to its excitotoxic, pro-oxidant and energy-disrupting 
properties. QUIN is a glutamatergic agonist acting on 
NMDAr, preferentially on discrete populations of these 
receptors containing the NR2A and NR2B subunits. 
This  metabolite  is  normally  present  at  nanomolar 
concentrations in human and rat brains,4 and in nano 
to micromolar concentrations in cerebrospinal fluid.5 
However, under inflammatory conditions, the KP is 
stimulated by cytokines—  particularly by interferon-γ 
(IFN-γ)—in macrophages. This results in the production 
of increased levels of QUIN and 3-HK.6 These altered 
levels have been observed in different inflammatory 
disorders of the CNS and these diseases also involve 
overactivation of NMDAr.2
The pattern of toxicity which results from increased 
QUIN  levels  is  considerably  complex  with  many 
mechanisms potentially involved. At a primary level, 
QUIN  exerts  excessive  excitation  of  NMDAr  and 
recruits  enhanced  cytoplasmic  Ca2+  concentrations, 
mitochondrial  dysfunction,  decreased  ATP  levels, 
cytochrome c release, selective loss of GABAergic 
and cholinergic neurons, and oxidative stress.1 Indeed, 
it may be assumed that most of the toxic cascades 
triggered or stimulated by QUIN eventually involve 
the formation of reactive oxygen and nitrogen   species 
(ROS and RNS, respectively), thus leading cells to 
oxidative damage as part of their degenerative pro-
cesses  (see  Fig.  1).  Thus,  when  injected  into  the 
brain, QUIN reproduces neurodegenerative events in 
rodents, resembling those observed in the brains of 
patients with Huntington’s disease (HD).7
More recently, there has been intensive research into 
kynurenines and this has provided new insights into 
the toxic mechanisms involved in neurodegenerative 
events with compromised KP metabolism. This review 
will offer an update on the recent findings on QUIN 
toxicity  in  order  to  bring  a  brief  and  “refreshing” 
perspective on this topic. We will specifically focus 
on  current  studies  and  discuss  what  areas  require 
  further characterization in this paradigm. Although we 
recognize the relevance of other mechanisms exerted 
by  QUIN  as  part  of  its  toxic  pattern—including 
mitochondrial dysfunction and inflammatory events—, 
we will not focus our attention on them in this occasion 
due to space limitations.
Quinolinate, excitotoxicity and 
Oxidative stress: A Recurrent 
Relationship
Excitotoxicity  is  a  deleterious  process  involving 
increased  intracellular  calcium  concentrations  in 
response to neuronal cell exposure to the persistent 
action  of  excitatory  amino  acids.  An  augmented 
Ca2+  influx  through  the  NMDAr-ion  channel  com-
plex is responsible for the activation of lethal meta-
bolic pathways ultimately activating lysis enzymes 
(protein  kinases,  phospholipases,  nitric  oxide  syn-
thase, proteases, etc.). This produces mitochondrial Quinolinic acid neurotoxicity
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alterations while increasing the ROS/RNS formation, 
and ultimately leads to apoptotic or necrotic death.1
The  exposure  of  corticostriatal  structures  to 
submicromolar  concentrations  of  QUIN  has  been 
shown  to  induce  neuronal  cell  death  through  an 
excitotoxic  mechanism,2  suggesting  that  the  toxin 
can  trigger  multiple  toxic  cascades  even  at  low 
concentrations. Moreover, excitotoxicity induced by 
QUIN has also been related to its ability to increase 
ROS/RNS formation and further oxidative damage. 
As  accepted  elsewhere,  the  brain  is  particularly 
susceptible  to  the  attack  of  ROS/RNS  due  to  a 
limited antioxidant defense system, a high demand of 
oxygen accompanied by a considerable dependency 
on a redox metabolism, and an enriched content of 
polyunsaturated fatty acid chains in cell membranes. 
This is particularly relevant as we now know that a 
high redox activity is necessary for the development 
and adequate functioning of the brain. In fact, ROS 
formation in the CNS should not be conceptualized 
as a mere toxic response as these species are critical 
for  cellular  signaling  pathways  and  oxidative 
homeostasis,  as  well  as  maintaining  energy  status, 
metabolite  concentrations  and  developmental  and 
survival responses.8 Therefore, it seems reasonable to 
consider that the brain is “loaded” with endogenous 
tools to handle and use ROS for its own benefits when 
the  formation  of  these  species  remains  at  certain 
controlled levels. However, when toxins like QUIN 
create a drastic scenario of exacerbated intracellular 
deleterious  signals  and  aberrant  oxidative  activity, 
excessive ROS leads to cell damage and death.
Previous studies have shown that QUIN possesses 
the ability to form complexes with Fe(II), thereby 
inducing ROS formation—especially hydroxyl radi-
cal (•OH), which in turn is responsible for DNA chain 
breakdown and lipid peroxidation—.9 This suggests 
that QUIN may cause additional oxidative events that 
could be partially independent on its direct capacity to 
stimulate NMDAr. Moreover, free radicals are known 
to increase glutamate release from nerve endings,10 
also  inhibiting  its  reuptake,11  hence  providing  an 
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Figure 1. Schematic representation of the classical proposed mechanisms by which quinolinic acid (QUIN) exerts toxicity in the Central Nervous System. 
Firstly, increased levels of QUIN in the extracellular domain are achieved after inflammatory-induced glial activation. QUIN can then act in several non-
excluding ways: (1) stimulating NMDAr and, together with other endogenous excitatory agents (glutamate), to induce excitotoxic events further leading to 
exacerbated intracellular calcium-mediating signaling and recruiting more calcium from internal storages (mitochondria and endoplasmic reticulum). QUIN 
can then act with other inner toxic signals, including mitochondrial dysfunction, cytochrome c release, reactive oxygen and nitrogen species (ROS/RNS) 
formation, protease activation, etc. Altogether, the above interactions lead to necrotic and apoptotic cell death. (2) QUIN directly interacts with free iron ions 
to form toxic complexes that exacerbate ROS/RNS formation, oxidative stress and excitotoxic events already in course. eventually, these toxic signals can 
be extended, thus reaching adjacent cells, either glial or neuronal, hence starting a degenerative chain in the brain.
Abbreviations: AA, arachidonic acid; COX, cyclooxygenase; L-KYN, L-kynurenine; LOX, lipooxygenase; SOD, superoxide dismutase.Pérez-De La Cruz et al
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alternative route by which QUIN could potentiate its 
primary excitotoxic mechanism.
Other studies report that the intrastriatal infusion 
of QUIN into rodents stimulates lipid peroxidation in 
this region within 2 h post-lesion,12 and these findings 
have  been  correlated  with  increased  extracellular 
levels  of  hydroxyl  radical  in  the  striatum.13  As  a 
result of these and other findings, the hypothesis that 
at least a fraction of the oxidative and cell damage 
induced by QUIN could correspond with components 
that  are  independent  of  NMDAr  overactivation 
formally emerged in the late 90’s—early 2000’s.13,14 
Supporting this hypothesis is that QUIN is known to 
generate a dysregulation in the oxidant/antioxidant 
ratio  by  affecting  the  reduced  glutathione:oxidized 
glutathione (GSH:GSSG) rate, as well as depleting the 
activity of Cu,  Zn-SOD at different times post-lesion.15 
In addition, the toxin has been shown to cause the 
early and time-dependent formation of peroxynitrite 
(ONOO-) as a key RNS contributing to this paradigm.16 
Moreover,  these  and  other  alterations  induced  by 
QUIN can be prevented by different antioxidants such 
as melatonin, sodium selenite, L-carnitine, etc.12,14,17 
For instance, it has been shown that piruvate, the final 
metabolite of glycolysis, exhibits antioxidant activity 
and  reduces  different  markers  of  oxidative  stress 
(4-hydroxynonenal,  8-hydroxyguanosine  and  ROS 
formation) induced by QUIN.18 In parallel, Ganzella 
and  coworkers19  demonstrated  that  4  hours  after 
hippocampal  infusion  of  QUIN  to  rats  (36.8  nM 
i.c.v.)  there  was  an  increased  formation  of  ROS 
which returned to basal levels 24 h after its infusion. 
However,  cell  damage  persisted  72  h  post-lesion. 
In the same study it was demonstrated that the total 
antioxidant capacity was increased 8 h post-lesion, 
which in turn can be considered as a compensatory 
response possibly contributing to the decreased levels 
of ROS found at later times. It was also speculated that 
these toxic pathways and processes initiated by ROS 
followed routes that were independent of the presence 
of  these  species.  These  and  other  studies  raised 
considerations about the substantial contribution of 
oxidative stress, coming from different sources, to 
the  toxic  paradigm  elicited  by  QUIN:  either  from 
mitochondrial  dysfunction,  excitotoxic  events  at 
membrane and cytoplasmic level, or from direct ROS 
formation through metal dissociation from proteins 
and further formation of pro-oxidant complexes.
Other  more  recent  studies  have  shown  that 
moderate activation of NMDAr by QUIN, combined 
with  mitochondrial  dysfunction  induced  by 
3-nitropropionic  acid  (3-NP),  can  synergistically 
augment the striatal degeneration in rodents through 
the dysregulation of intracellular Ca2+. This suggests a 
lack of hypersensitization of NMDAr.20 This synergic 
model is relevant for mimicking some pathological 
alterations  of  neurological  disorders—such  as 
Huntington’s disease (HD)—combining excitotoxic 
events  and  deficient  energy  metabolism.  Based 
on these findings, it was further demonstrated that 
mitochondrial dysfunction and oxidative damage are 
potentiated when these two toxins, 3-NP + QUIN are 
simultaneously added to synaptosomal fractions and 
striatal slices at subtoxic concentrations. This noxious 
synergism  is  likely  to  be  dependent  on  protease 
activation.21
What’s new?
Key  insights  into  QUIN  toxicity  have  recently 
been  described.  For  example,  QUIN  not  only 
induces damage to neurons, but also to glial cells. 
This discovery presents a new perspective on the 
toxic  properties  of  this  agent  and  highlights  the 
importance  of  designing  therapeutic  alternatives 
for  neurological  disorders  involving  these  cells. 
In  this  regard,  the  findings  of  Guillemin  and 
coworkers,22 which showed that QUIN is capable of 
inducing a certain degree of apoptosis in cultured 
human  astrocytes  is  particularly  relevant  for 
disorders involving high concentrations of QUIN in 
cerebrospinal fluid, including HAD. Moreover, the 
recent discovery and characterization of the KP in 
cultured human neurons and neuroblastoma cells is 
not only enlightening itself, but also describes for 
the first time a differential role for the KP in neuronal 
protection  and/or  degeneration.23  Interestingly, 
these authors found that the differential capacity of 
primary cultures and adult neurons to produce the 
neuroprotectant picolinic acid (PIC) is in contrast 
with  the  metabolic  orientation  of  tumoral  cells 
to  synthesize  QUIN.  These  differences  establish 
important  clues  to  understanding  the  nature  of 
modulatory  actions  of  the  KP  in  neuroprotection 
or  neurotoxicity  through  immune  and  tumor 
regulation.  Shortly  thereafter,  Owe-Young  and 
coworkers24 extended the investigation of the KP to Quinolinic acid neurotoxicity
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the components of blood-brain-barrier, endothelial 
cells  and  pericytes.  Under  normal  conditions 
endothelial  cells  produced  KYNA  and  pericytes 
synthesized  PIC.  However,  under  conditions  of 
immune  activation  both  cell  types  basolaterally 
secreted  high  amounts  of  kynurenine  for  further 
conversion to QUIN by perivascular macrophages. 
Once again, triggering mechanisms such as immune 
activation through inflammatory processes is likely 
to stimulate different cell types to produce QUIN, 
which in turn could account for local neurotoxicity. 
Braidy  and  coworkers25  further  demonstrated  that 
the concentration of different metabolites from the 
KP  determines  whether  they  stimulate  beneficial 
effects  for  human  glial  and  neuronal  cells  (such 
as  NAD+  synthesis)  or  induce  damaging  events 
and  cell  death.  It  was  concluded  from  this  study 
that  some  metabolites  like  3-hydroxyanthanilic 
acid, 3-HK, QUIN and PIC, at low concentrations 
(100  nM),  clearly  stimulated  NAD+  formation, 
while above this concentration, the same metabolites 
induced cell damage. In parallel, the same authors 
demonstrated that at low concentrations (,50 nM), 
QUIN is a substrate for NAD+ synthesis, whereas 
at abnormally high concentrations (.150 nM) this 
metabolite  can  mediate  astrocytic  and  neuronal 
inflammation  and  damage  though  a  mechanism 
involving  excitotoxicity,  induction  of  nitric  oxide 
synthase (NOS) and further nitric oxide-stimulated 
oxidative  stress.26  Taken  together,  these  studies 
certainly constitute valuable advances in this area 
and will change our perception on the role of KP 
modulation in neurodegenerative disorders.
In 2007, Poeggeler and coworkers27 discovered a 
key component of the NMDA- and QUIN-induced 
NMDAr-mediated striatal toxicity. This component 
was elegantly revealed using dopaminergic agonists 
and antagonists. When administering dopaminergic 
agonists—d-amphetamine  and  apomorphine—,  the 
striatal  lesion  induced  by  NMDA  and  QUIN  was 
enhanced and KYNA levels were decreased. In con-
trast, pretreatment with the antagonists abolished the 
potentiated NMDAr-mediated toxicity. As a result of 
these findings, the modulation of dopaminergic activ-
ity should be considered in the future when designing 
therapeutic strategies against QUIN toxicity.   However, 
the precise magnitude of the dopaminergic contribu-
tion to these paradigms is yet to be delineated.
More  specifically  with  regard  to  QUIN  and 
oxidative stress, a recent and exciting investigation 
relating to redox modulation at a molecular level in 
the toxic model evoked by QUIN has been described. 
  Tert-butyl  hydroquinone  (tBHQ),  a  well  known 
inducer of nuclear translocation of the transcription 
nuclear factor Nrf2 (which in turn is responsible for 
the activation of antioxidant response elements (ARE) 
and the consequent synthesis of phase 2 antioxidant 
enzymes) was shown to be able to prevent the lipid 
peroxidation and mitochondrial dysfunction caused 
by QUIN in rat striatal slices.28 This effect correlated 
with a partial recovery in the activity of glutathione-
S-transferase, an enzyme involved in the modulation 
of  nuclear  Nrf2  translocation. As  expected,  QUIN 
itself decreased the nuclear expression of Nrf2, thus 
suggesting  a  compromised  antioxidant  defense  in 
the toxic model. This study is particularly relevant 
for future considerations in this field as it suggests 
that QUIN toxicity is associated with a reduction of 
antioxidant defenses at a molecular level by silenc-
ing phase 2 antioxidant enzymes. As a result of these 
studies,  therapeutic  alternatives  designed  to  stimu-
late Nrf2 translocation and further phase 2 enzyme 
expression should be considered to mitigate the toxic 
events produced by QUIN.
In addition to these findings, QUIN has also been 
shown to produce an early increase in the expression 
of the receptor for advanced glycation end-products 
(RAGE)  in  the  rat  striatum.  This  can  be  partially 
considered a marker of oxidative stress as AGEs result 
from intense activity of ROS and carbonyl compounds, 
and RAGE has been shown to be overexpressed in 
different neurodegenerative conditions.29 Therefore, 
as QUIN is capable of inducing RAGE upregulation, 
this could be a novel event accounting for QUIN-
induced  oxidative  stress.  Therefore,  interesting 
mechanistic alternatives are now available. Moreover, 
the recent characterization of a potential contributing 
role  for  NAD(P)H  oxidase—an  enzyme  complex 
catalyzing the formation of superoxide anion from 
oxygen—to  QUIN-induced  toxicity  in  a  NMDAr-
dependent  manner,  provides  new  evidence  on  the 
close relationship between excitotoxic and oxidative 
mechanisms in this model.30
Kumar’s  group  continues  with  an  extensive 
search for therapeutic alternatives to ameliorate the 
deleterious effects produced by QUIN in the rat brain. Pérez-De La Cruz et al
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This group is constantly testing and confirming the 
effects  of  targeting  the  pro-oxidant,  inflammatory 
and metabolic components of this model using drugs 
directed to ameliorate each toxic event. For example, 
they  recently  presented  evidence  showing  that 
montelukast,  a  leukotriene  receptor  antagonist  and 
anti-inflammatory  agent,  attenuates  QUIN-induced 
neurotoxicity,  oxidative  stress,  aberrant  behavior 
and mitochondrial alterations.31 This group has also 
shown that statins such as atorvastatin, simvastatin 
and fluvastatin, can reduce QUIN induced toxicity at 
the same levels mentioned above.32 Although statins 
are known to be cholesterol-lowering drugs inducing 
inhibition of HMG Co-A reductase—the rate-limiting 
enzyme  in  cholesterol  biosynthesis—,  the  authors 
were more interested in exploring the antioxidant and 
anti-inflammatory potential of these molecules. Other 
groups have made similar approaches, assessing the 
positive  effects  of  antioxidant  and  neuroprotective 
agents in this toxic paradigm. Some agents exhibiting 
protective/antioxidant  properties  against  QUIN 
include the polyamine spermine.33 This was assumed 
to modulate the polyamine binding site at the NMDAr 
function and also exert antioxidant effects—, the energy 
precursor and antioxidant L-carnitine,17 the selective 
neuronal  nitric  oxide  synthase  inhibitor    Nomega-
Nitro-l-arginine-methyl esther34—acting by recovering 
the protein tyrosine phosphorylation pattern affected 
by  QUIN—,  the  antioxidant  element  selenium35—
acting by reducing the proapoptotic signaling derived 
from  NF-κB  pathway  and  stimulating  glutathione 
peroxidase activity—, the free radical scavenger and 
signaling molecule melatonin,36 and the singlet oxygen 
and  superoxide  scavenger  6-hydroxymelatonin,37 
among  several  others.  Recently,  our  group  has 
carried out studies in vitro and in vivo to investigate 
whether the antioxidant S-allylcysteine can recover 
the  synaptosomes  from  the  toxic  insult  caused  by 
QUIN, even when this agent is administered in post-
lesion schemes.38 The findings of this study suggest 
that the optimum time window for pharmacological 
intervention  to  achieve  functional  preservation  of 
nerve endings is short, 1 to 3 h post-lesion.
Together, these and other therapeutic approaches 
against QUIN toxicity highlight the benefits of target-
ing the different toxic levels exerted by this endog-
enous metabolite in nerve tissue. However, a more 
reasonable  design  of  pharmacological  alternatives 
for  pathologies  involving  QUIN  as  a  pathogenic 
factor  should  consider  a  more  realistic  condition 
occurring in these disorders: an imbalance between 
KP  metabolites,  specifically  between  QUIN  and 
KYNA. Müller and coworkers39 have addressed this 
issue by revising and discussing two opposing pat-
terns of type-1 (T-helper 1) and type-2 (T-helper 2) 
immune responses likely associated with differential 
activation of KP enzymes. These responses result in 
either an increased production of KYNA in schizo-
phrenia or decreased KYNA levels in depression, all 
contrasting with increased levels of QUIN in differ-
ent neurodegenerative disorders. Furthermore, there 
is  a  differential  activation  of  microglia  and  astro-
cytes during inflammatory episodes, which adds to 
this imbalance.
Finally, one of the most exciting and promising 
recent  findings  is  the  demonstration  of  a  differen-
tial susceptibility of mice carrying a polyglutamine 
expanded  CAG  tract  corresponding  to  mutant 
  Huntingtin  (YAC128)  to  the  neurotoxic  actions  of 
QUIN  during  the  presymptomatic  stages  (before 
obvious phenotypic changes occurr), and a   resistance 
to  QUIN  toxicity  in  10-month-old  symptomatic 
mice.40 These observations could correlate with what 
may be happening in the brains of HD patients that 
currently show enhanced levels of QUIN during the 
first stages of the disease. In addition, presymptom-
atic mice exhibited increased function of NMDAr, 
while symptomatic mice presented the opposite. This 
is a remarkable contribution to the HD and QUIN 
research fields as it offers an elegant explanation for 
the dynamic nature of the mutant htt-mediated exci-
totoxic phenotype and the potential role of altered KP 
in this disorder. However, the precise mechanisms 
by which this differential susceptibility is occurring 
remain to be elucidated.
conclusions
QUIN has gained considerable relevance in biomedi-
cal research, and a series of specific factors contribute 
to this concept: (1) This is an endogenous metabo-
lite derived from a major catabolic pathway that is 
present in several mammalian tissues; (2) it has been 
implicated in cell damage in a wide range of psychiat-
ric, neurological and systemic disorders; (3) QUIN is 
a molecule with neuroactive properties as a moderate 
agonist of NMDAr; (4) it is widely employed as an Quinolinic acid neurotoxicity
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excitotoxic model of neuronal damage in biomedical 
research; (5) it may also influence a series of toxic 
mechanisms that could be partially independent of its 
primary interaction with NMDAr; and finally, (6) the 
modulation of its endogenous production offers inter-
esting possibilities for a therapeutic intervention in all 
disorders combining excitotoxicity, oxidative stress, 
energy depletion and inflammation. Thus, the diver-
sity of toxic mechanisms that have been demonstrated 
for QUIN suggests a major role for this molecule at 
different physiologic and physiopathologic levels in 
the CNS. Together,  this  toxic profile  suggests  that 
QUIN is a metabolite with unique properties as a tox-
icological tool for research. The characterization of 
its damaging mechanisms is relevant for the explana-
tion of physiopathologic events occurring in several 
neurodegenerative disorders.
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